NVDA
NVIDIA
-- 134.250 PLTR
Palantir
-- 76.070 TSLA
Tesla
-- 436.230 AVGO
Broadcom
-- 224.800 AMD
Advanced Micro Devices
-- 126.910 
NEWS
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
Monday, 9th December at 8:45 am
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level
Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21 (48%) evaluable monotherapy patients, and importantly included one patient dosed at the MTD who had a partial response (PR) by RESIST criteria (a 45% decrease from baseline)
Together, these data suggest clinical benefit when SON-1010 is administered as a monotherapy
Monday, 9th December at 8:45 am
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level
Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21 (48%) evaluable monotherapy patients, and importantly included one patient dosed at the MTD who had a partial response (PR) by RESIST criteria (a 45% decrease from baseline)
Together, these data suggest clinical benefit when SON-1010 is administered as a monotherapy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment